Cancer Res Treat. 2019;51(1):223-239.

Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer.

, , , , , , , , , , , , , , ,

제1저자 김진원 · 교신저자 이근욱

PMID 30584995 PMC6333995 DOI 10.4143/crt.2018.073 IF 4.2 혈액종양내과

소속 (14)

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Department of Oncology/Hematology, School of Medicine, Kyungpook National University, Daegu, Korea.
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University College of Medicine, Hwasun, Korea.
Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University College of Medicine, Daegu, Korea.
Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea.
Department of Internal Medicine, Hallym University Medical Center, Hallym University, Anyang, Korea.
Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea.
Department of Internal Medicine, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Korea.
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University College of Medicine, Yangsan, Korea.
Medical Department of Genzyme, Sanofi Korea, Seoul, Korea.

Abstract

PURPOSE The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC).

MATERIALS AND METHODS Thiswas a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians.

RESULTS Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, "a little" changes (differences of 5-10 points from baseline)were observed in some of the functioning or symptom scales; none of the QOL scales showed either "moderate" or "very much" change (i.e., ≥ 11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients' QOL was maintained to a similar degree, regardless of their actual response to chemotherapy.

CONCLUSION This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patientswith advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.

Keywords

Advanced gastric cancerFirst-line palliative chemotherapyQuality of life

Figures

**Fig. 2.** Overall (A) and progression-free survival (B) of first-line palliative chemotherapy. CI, confidence interval.

**Fig. 3.** Comparison of overall (A) and progression-free survival (B) of first-line palliative chemotherapy between patients aged < 70 and ≥ 70 years. CI, confidence interval.

**Fig. 4.** Changes in quality of life domains during first-line palliative chemotherapy. QLQ, Quality of Life Questionnaires; QOL, quality of life.

그림 출처: PubMed Central 공개 논문 (PMC6333995)

Conflict of interest statement

This study was sponsored by Sanofi-Aventis Korea Co., Ltd.

그 밖의 정보